We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Unusual Sugar Facilitates Long-Term Survival of Leishmania Parasites

By LabMedica International staff writers
Posted on 22 Sep 2019
A team of British and Australian parasitologists has determined that the Leishmania parasite is able to survive for long periods of time in human immune cells due to its ability to synthesize the non-canonical carbohydrate reserve, mannogen, which is composed of beta-1,2-mannan oligosaccharides.

Leishmania is a genus of protozoan parasites that is responsible for the disease leishmaniasis, which currently affects around six million people in 98 countries. More...
The parasites are spread by sandflies of the genus Phlebotomus in the Old World, and of the genus Lutzomyia in the New World. At least 93 sandfly species are known or probable vectors worldwide. The primary hosts of the parasites are vertebrates; Leishmania commonly infects hyraxes, canids, rodents, and humans.

Leishmania parasites are able to persist for many years in their human host by sequestering themselves inside immune cells, such as macrophages. The infected macrophages may eventually generate large granuloma lesions that can lead (depending on the species of parasite and host immune status) to open ulcerating sores, organ damage and, in some cases, death.

The molecular basis of long-term survival of the parasites within host cells was not known. Recently, however, investigators at the University of York (United Kingdom) and the University of Melbourne (Australia) reported the discovery that Leishmania were able to synthesize the non-canonical carbohydrate reserve, mannogen, which is composed of beta-1,2-mannan oligosaccharides. Furthermore, the investigators identified a class of dual-activity mannosyltransferase/phosphorylases (MTPs) enzymes that catalyzed both the sugar nucleotide-dependent biosynthesis and phosphorolytic turnover of mannogen.

Structural and phylogenic analysis showed that while the MTPs were structurally related to bacterial mannan phosphorylases, they constituted a distinct family of glycosyltransferases that had likely been acquired by horizontal gene transfer from gram-positive bacteria. The seven MTPs catalyzed the constitutive synthesis and turnover of mannogen. This metabolic “rheostat” protected the obligate intracellular parasite stages (amastigotes) from nutrient excess, and was essential for thermotolerance and parasite infectivity in the mammalian host.

Senior author Dr. Malcolm McConville, professor of molecular parasitology and microbiology at the University of Melbourne, said, "As mannogen metabolism is critical for the survival of these parasites, developing inhibitors to block the enzymes that regulate this carbohydrate store is a potential way to specifically kill Leishmania parasites. We can exploit the parasite's food preference for mannogen and specifically target this metabolic pathway, without side effects to humans. Similar enzymes and carbohydrates are made by other pathogens, such as the bacteria that cause tuberculosis, and this work may contribute to developing new classes of drugs to treat other infectious diseases."

The Leishmania study was published in the September 11, 2019, issue of the journal Cell Host & Microbiology.

Related Links:
University of York
University of Melbourne


Gold Member
Aspiration System
VACUSAFE
Online QC Software
Acusera 24•7
Automated Urinalysis Solution
UN-9000
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.